Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine.
Romanova J, Krenn BM, Wolschek M, Ferko B, Romanovskaja-Romanko E, Morokutti A, Shurygina AP, Nakowitsch S, Ruthsatz T, Kiefmann B, König U, Bergmann M, Sachet M, Balasingam S, Mann A, Oxford J, Slais M, Kiselev O, Muster T, Egorov A. Romanova J, et al. Among authors: morokutti a. PLoS One. 2009 Jun 19;4(6):e5984. doi: 10.1371/journal.pone.0005984. PLoS One. 2009. PMID: 19543385 Free PMC article.
Development of a live-attenuated influenza B DeltaNS1 intranasal vaccine candidate.
Wressnigg N, Voss D, Wolff T, Romanova J, Ruthsatz T, Mayerhofer I, Reiter M, Nakowitsch S, Humer J, Morokutti A, Muster T, Egorov A, Kittel C. Wressnigg N, et al. Among authors: morokutti a. Vaccine. 2009 May 11;27(21):2851-7. doi: 10.1016/j.vaccine.2009.02.087. Epub 2009 Mar 11. Vaccine. 2009. PMID: 19366569
Mutations affecting the stability of the haemagglutinin molecule impair the immunogenicity of live attenuated H3N2 intranasal influenza vaccine candidates lacking NS1.
Nakowitsch S, Wolschek M, Morokutti A, Ruthsatz T, Krenn BM, Ferko B, Ferstl N, Triendl A, Muster T, Egorov A, Romanova J. Nakowitsch S, et al. Among authors: morokutti a. Vaccine. 2011 Apr 27;29(19):3517-24. doi: 10.1016/j.vaccine.2011.02.100. Epub 2011 Mar 12. Vaccine. 2011. PMID: 21406268
Single HA2 mutation increases the infectivity and immunogenicity of a live attenuated H5N1 intranasal influenza vaccine candidate lacking NS1.
Krenn BM, Egorov A, Romanovskaya-Romanko E, Wolschek M, Nakowitsch S, Ruthsatz T, Kiefmann B, Morokutti A, Humer J, Geiler J, Cinatl J, Michaelis M, Wressnigg N, Sturlan S, Ferko B, Batishchev OV, Indenbom AV, Zhu R, Kastner M, Hinterdorfer P, Kiselev O, Muster T, Romanova J. Krenn BM, et al. Among authors: morokutti a. PLoS One. 2011 Apr 7;6(4):e18577. doi: 10.1371/journal.pone.0018577. PLoS One. 2011. PMID: 21490925 Free PMC article.
A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1.
Wacheck V, Egorov A, Groiss F, Pfeiffer A, Fuereder T, Hoeflmayer D, Kundi M, Popow-Kraupp T, Redlberger-Fritz M, Mueller CA, Cinatl J, Michaelis M, Geiler J, Bergmann M, Romanova J, Roethl E, Morokutti A, Wolschek M, Ferko B, Seipelt J, Dick-Gudenus R, Muster T. Wacheck V, et al. Among authors: morokutti a. J Infect Dis. 2010 Feb 1;201(3):354-62. doi: 10.1086/649428. J Infect Dis. 2010. PMID: 20039806 Clinical Trial.